Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC With HER2 Alterations, a Phase II Study

NCT05847764 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05847764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05847764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC With HER2 Alterations, a Phase II Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2023
Completion date
May 31, 2025
Enrollment
95 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

disitamab vedotin, erbb2 mutation-related tumors, non small cell lung cancer, rc48